The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Promising outlooks for venetoclax combinations for MM
Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, presents the results of some preclinical and clinical trials investigating the effects of venetoclax in combination with proteasome inhibitors at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden. Dr Kumar discusses the drugs venetoclax has been combined with and the results of these combinations, all of which seem promising regardless of whether the patients had previously been exposed to drugs of the same kind.
